Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Achieve Life Sciences
John Bencich has been named CEO of Achieve Life Sciences. Prior to this appointment, Bencich served as the company’s chief financial and operating officer. Cindy Jacobs, former chief medical officer of Achieve, will now serve as president of the company.
Adamas Pharmaceuticals has tapped Adrian Quartel to serve as its chief medical officer. Quartel most recently was global head of medical affairs at BioMarin.
Jennifer Jarrett has returned to her position as chief operating officer at Arcus Biosciences after a stint as Uber Technologies’ vice president of corporate development and capital markets.
Kennon Broadhurst has been appointed vice president of global marketing at BioAgilytix Labs. Most recently, Broadhurst served as global marketing lead for oncology and hematology biosimilars
Boehringer Ingelheim Fremont
Lars Dreesman will take the helm at Boehringer Ingelheim’s (BI) U.S. biopharma development and manufacturing business in California. Dreesman leaves his position as head of BI’s global quality systems and product compliance.
Day One Biopharmaceuticals
Day One Biopharmaceuticals has tapped Jeremy Bender as its new CEO. Bender joins Day One from Gilead Sciences, where he served as vice president of corporate development.
Ferdinand Massari has been appointed chief medical officer of Deep Genomics. Massari was most recently the co-founder and leader of Kintai Therapeutics.
Keith Howard has been named Enesi Pharma’s chief scientific officer. Formerly, Howard was chief development officer
Freeline Therapeutics has promoted its vice president of research, Romuald Corbau, to take on the role of chief scientific officer.
Robert Greif has been named CEO of H-CYTE, a regenerative cellular therapeutics developer. Greif most recently served as chief commercial officer and business development leader at Atox Bio.
Biotech company Inotrem has named Delphine Joyeux director of regulatory affairs and quality assurance. Most recently, Joyeux was head of regulatory affairs at AB Science. Inotrem also appointed Simon Lambden, a current clinical lecturer at Cambridge University, to the role of head of medical science.
Philippe Lopes-Fernandes has been appointed executive vice president and chief business officer of Ipsen. Previously, Lopes-Fernandes was the senior vice president and global head of business development and alliance management at Merck.
Kaleido Biosciences’s new president and CEO is Daniel Menichella. Menichella comes to Kaleido from his former position as CEO of CureVac.
Matrivax Research and Development
Enda Moran has been appointed vice president of process development and chemistry, manufacturing and controls (CMC) at Matrivax Research and Development. Most recently, Moran was the vice president of CMC development and clinical manufacturing at Northern Biologics.
Medable has appointed Mary Costello head of its site and investigator network. Costello was most recently vice president of clinic development and patient advocacy. Rasmus Hogreffe, former head of virtual trials at LEO Innovation Lab, has been appointed by Medable to vice president of decentralized trial innovation. Additional hires include Steve Lesser to vice president of partner strategy and Heidi Pfefferkorn to decentralized solutions leader. Lesser was most recently the lead solutions architect of real-world evidence at SHYFT Analytics, and Pfefferkorn was previously the director of external development operations at Novartis. The former chief marketing officer of GeoPhy, David Swanger, was also named by Medable as its new senior vice president of marketing. In addition, Ching Tian, who previously served as general manager of data and digital at Novartis, was appointed senior vice president of strategy and solutions.
Karen Zinkewich-Péotti has taken the helm of Montis Biosciences as its CEO. Zinkewich-Péotti was most recently a senior vice president at Ipsen.
Daniela Brunner has been appointed chief innovation officer of PsychoGenics. Brunner joined PsychoGenics in 1999 and previously served as its director and senior vice president of behavioral R&D. PsychoGenics has also appointed Geoffrey Varty executive vice president of research operations and Leslie Street vice president of medicinal chemistry. Varty and Street previously served as head of in vivo pharmacology at Merck and senior director and head of medicinal chemistry at Cortex Pharmaceuticals, respectively.
RespireRx Pharmaceuticals has appointed David Dickason senior vice president of preclinical product development. Prior to this appointment, Dickason held senior technical roles at iCeutica and Alkermes.
Valerie Odegard, chief scientific officer of Silverback Therapeutics, has added president to her list of duties at the company. Silverback has also promoted Naomi Hunder from her previous position of senior vice president of clinical research and development to the role of chief medical officer.
Sonoma Biotherapeutics has appointed Leonard Dragone, former vice president for early clinical development at Janssen Biopharma, to chief medical officer. Sejal Hall has also joined Sonoma as its vice president of portfolio, program and alliance management. Most recently, Hall was executive director, research operations and program management at Audentes Therapeutics. Susan Lacy has also been hired by Sonoma to serve as vice president of discovery. Lacy previously served in various director roles during a 20-year tenure at AbbVie.
Yann Brun, former managing director of Exeltis, has assumed the role of executive vice president and head of global development, portfolio, regulatory and business development/licensing at the STADA Group.
TriSalus Life Sciences
TriSalus Life Sciences has named Steven Katz as the company’s chief medical officer. Katz had served as the chief medical adviser of TriSalus since 2018.
Scott Meyer, chief operating officer of Vertice Pharma, has been promoted to CEO of the company. Prior to joining Vertice in 2016, Meyer was vice president and general manager of Fougera.
Tom Hochuli, former cell and gene therapy operations head at Lonza, has been named global CEO of Vibalogics.